Melvin Lee Kiang Chua, MBBS, FRCR, PhD

Melvin Lee Kiang Chua, MBBS, FRCR, PhD

Senior Consultant, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore; Assistant Professor, Duke-NUS Medical School
 

Dr Melvin Chua is a clinician-scientist, and Principal Investigator of the Precision Radiation Oncology Programme, Division of Radiation Oncology, with a track record of more than 13,000,000 SGD of competitive grant funding (as primary and joint applicant). He is also supported by the NMRC Clinician-Scientist Award. He currently leads his research focusing on precision medicine using prognostic and predictive biomarkers, and experimental therapeutics in the management of prostate and nasopharynx cancers. In particular, his group is interested in using modern “omics” approaches to interrogate the molecular underpinnings of radioresistance of these tumours; layering these datasets with validated prognostic clinical tools the group has developed (www.PRANCIS.Medlever.com) to improve clinical risk stratification and precision treatment of patients. Separately, the programme also recently joined the PRACTICAL Prostate Cancer Genomics Consortia, a global consortium that aims to characterise prostate cancer risk susceptibility genes in 200,000 men across different racial ancestries.

Dr Chua is also currently involved in a National Research Foundation-funded 5-year clinical research programme (as the co-Principal Investigator) to investigate novel mechanisms of proton beam therapy (PBT) targeting of tumours; the programme themes encompass characterising exclusive genomic and epigenomic alterations induced by PBT; differential immune responses between PBT and conventional photon irradiation; testing novel drug and nanoparticle conjugate combinations with PBT; and developing novel imaging tools to survey for treatment responses.

Dr. Chua’s other academic activities include his roles as Editor-in-Chief, Annals of Nasopharynx Cancer; Association Senior Editor for the Head and Neck Cancer Section of the Red Journal – the official journal for the American Society of Radiation Oncology; Associate Editor of the British Journal of Radiology; including four other editoral boards. He is a member of the ASCO Multidisciplinary Cancer Management Course working group, and is affiliated with ASCO, AACR, ASTRO, ESMO and ESTRO. He also sits on local and external grant review panels, including the Canadian Cancer Society. Dr. Chua has spoken at over 70 scientific symposiums, and has published over 50 peer-reviewed papers, including high-impact articles in The Lancet, Nature, Cell, Journal of Clinical Oncology, JAMA Oncology, European Urology, Annals of Oncology, Nature Communications, and Clinical Cancer Research. Notably, his review article on Nasopharynx Cancer in The Lancet has received 523 citations (as of 31 Jan 2019). His highlighted awards include multiple Conquer Cancer Foundation ASCO Merit Awards (2013, 2016, and 2017), the National Medical Research Council Singapore Transition Award (2014) and Clinician-Scientist (Investigator) Award (2018), and the Canadian Urologic Oncologic Research Award (2015).